Insulin initiation in type 2 diabetes: What are the treatment regimen options and how can we best help patients feel empowered?

Journal of the American Academy of Nurse Practitioners

Volumn 24, Issue SUPPL.1, 2012, Pages 249-259

  Spollett, Geralyn R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Insulin therapy; Patient education; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; INCRETIN; INSULIN; METFORMIN;

ALGORITHM; ARTICLE; BEHAVIOR; DECISION MAKING; DISEASE COURSE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSE PRACTITIONER; NURSING; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; TIME;

ALGORITHMS; DECISION MAKING; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; METFORMIN; NURSE PRACTITIONERS; PATIENT SATISFACTION; POWER (PSYCHOLOGY); TIME FACTORS;

EID: 84860650232     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2012.00721.x     Document Type: Article

References (103)

1. ADA (American Diabetes Association). (2011). Standards of medical care in diabetes. Diabetes Care, 34(Suppl. 1), S11-S61.
2. Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010). Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. American Journal of Medicine, 123, 468.e9-468.e17.
3. Barnett, A. H., & Owens, D. R. (1997). Insulin analogues. Lancet, 349, 47-51.
4. Blonde, L., Merilainen, M., Karwe, V., & Raskin, P.; TITRATE Study Group. (2009). Patient-directed titration for achieving glycemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Diabetes, Obesity & Metabolism, 11, 623-631.
5. Bolli, G. B., & Owens, D. R. (2000). Insulin glargine. Lancet, 356, 443-445.
6. Brange, J. (1997). The new era of biotech insulin analogues. Diabetologia, 40(Suppl. 2), S48-S53.
7. Brange, J., Owens, D. R., Kang, S., & Vølund, A. (1990). Monomeric insulins and their experimental and clinical implications. Diabetes Care, 13, 923-954.
8. Brange, J., & Vølund, A. (1999). Insulin analogs with improved pharmacokinetic profiles. Advanced Drug Delivery Reviews, 35, 307-335.
9. Brod, M., Kongsø, J. H., Lessard, S., & Christensen, T. L. (2009). Psychological insulin resistance: Patient beliefs and implications for diabetes management. Quality of Life Research, 18, 23-32.
10. Brubaker, P. L., & Drucker, D. J. (2004). Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology, 145, 2653-2659.
11. Buse, J., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J., ... for the LEAD 6 Study Group. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 374, 39-47.
12. Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y., Rosenstock, J. (2011). Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Annals of Internal Medicine, 154, 103-112.
13. Buse, J. B., Wolffenbuttel, B. H., Herman, W. H., Shemonsky N. K., Jiang, H. H., Fahrbach, J. L., Martin, S. A. (2009). DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care, 32, 1007-1013.
14. Ceriello, A. (2003). The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia, 46(Suppl. 1), M9-M16.
15. Chapman, T. M., Noble, S., & Goa, K. L. (2002). Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 62, 1945-1981. Erratum in: Drugs, (2003) 63, 512.
16. Charbonnel, B., & Cariou, B. (2011). Pharmacological management of type 2 diabetes: The potential of incretin-based therapies. Diabetes, Obesity & Metabolism, 13, 99-117.
17. Dailey, G. E. 3rd. (2005). Early insulin: An important therapeutic strategy. Diabetes Care, 28, 220-221.
18. Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., & Gomis, R.; ATLANTUS Study Group. (2005). Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care, 28, 1282-1288.
19. Davis, S. N., & Renda, S. M. (2006). Psychological insulin resistance: Overcoming barriers to starting insulin therapy. Diabetes Educator, 32(Suppl. 4), 146S-152S.
20. DECODE study group on behalf of the European Diabetes Epidemiology Group. (1999). Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet, 354, 617-621.
21. DeFronzo, R. A. (2004). Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America, 88, 787-835.
22. DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, 1092-1100.
23. DeWitt, D. E., & Hirsch, I. B. (2003). Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA, 289, 2254-2264.
24. Diabetes Attitudes, Wishes and Needs (DAWN) study. (2003). Barriers to treatment. Retrieved from
25. Dornhorst, A., Lüddeke, H. J., Koenen, C., Meriläinen, M., King, A., Robinson, A., ... PREDICTIVE Study Group. (2008). Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes, Obesity & Metabolism, 10, 75-81.
26. Duckworth, W., & Davis, S. N. (2007). Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: A review of clinical studies. Journal of Diabetes and its Complications, 21, 196-204.
27. Dunning, T. (2004). Exploring the world mythology of diabetes. Diabetes Voice, 49, 30-33.
28. Fonseca, V., Davidson, J., Home, P., Snyder, J., Jellinger, P., Dyhr Toft, A., & Barnett, A. (2010). Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials. Current Medical Research and Opinion, 26, 1621-1628.
29. Fonseca, V., Schweizer, A., Albrecht, D., Baron, M.A., Chang, I., & Dejager, S. (2007). Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia, 50, 1148-1155.
30. Funnell, M. M., Kruger, D. F., & Spencer, M. (2004). Self-management support for insulin therapy in type 2 diabetes. Diabetes Educator, 30, 274-280.
31. Gao, Y., Yoon, K. H., Chuang, L. M., Mohan, V., Ning, G., Shah, S., ... Brodows, R. (2009). Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Research and Clinical Practice, 83, 69-76.
32. Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., ... LEAD-3 (Mono) Study Group. (2009). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet, 373, 473-481.
33. Garber, A. J., Wahlen, J., Wahl, T., Bressler, P., Braceras, R., Allen, E., & Jain, R. (2006). Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity & Metabolism, 8, 58-66.
34. Gautier, J. F., Choukem, S. P., & Girard, J. (2008). Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & Metabolism, 34(Suppl. 2), S65-S72.
35. Haak, T., Tiengo, A., Draeger, E., Suntum, M., Waldhäusl, W. (2005). Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 7, 56-64.
36. Harris, M. I., Klein, R., Welborn, T. A., & Knuiman, M. W. (1992). Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care, 15, 815-819.
37. Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004). The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharmaceutical Research, 21, 1498-1504.
38. Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., & Home, P. (2006). A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care, 29, 1269-1274.
39. Hirsch, A. B., & Brownlee, M. (2005). Should minimal blood glucose variability become the gold standard of glycemic control Journal of Diabetes and its Complications, 19, 178-181.
40. Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., ...4-T Study Group. (2009). Three-year efficacy of complex insulin regimens in type 2 diabetes. New England Journal of Medicine, 361, 1736-1747.
41. Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., ... 4-T Study Group. (2007). Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New England Journal of Medicine, 357, 1716-1730.
42. Home, P., & Kurtzhals, P. (2006). Insulin detemir: From concept to clinical experience. Expert Opinion on Pharmacotherapy, 7, 325-343.
43. Home, P. D., Boulton, A. J. M., Jimenez, J., Landgraf, R., Osterbrink, B., & Christiansen, J. S.; on behalf of the Worldwide Initiative for Diabetes Education (WorldWIDE). (2003). Issues relating to the early or earlier use of insulin in type 2 diabetes. Practical Diabetes International, 20, 63-71.
44. Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Siebenhofer, A. (2007). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 2, CD005613.
45. IDF. (2005). Clinical guidelines task force. Global guideline for type 2 diabetes. Brussels, Belgium: International Diabetes Federation, Retrieved from
46. IDF. (2007).Clinical guidelines task force. Guideline for management of postmeal glucose. Brussels: International Diabetes Federation. Retrieved from
47. Jeavons, D., Hungin, A. P., & Cornford, C.S. (2006). Patients with poorly controlled diabetes in primary care: Healthcare clinicians' beliefs and attitudes. Postgraduate Medical Journal, 82, 347-350.
48. Kadowaki, T., Namba, M., Yamamura, A., Sowa, H., Wolka, A. M., & Brodows, R.G. (2009). Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocrine Journal, 56, 415-424.
49. Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 444, 840-846.
50. Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D. L., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28, 1083-1091.
51. Korytkowski, M. (2002). When oral agents fail: Practical barriers to starting insulin. International Journal of Obesity and Related Metabolic Disorders, 26(Suppl. 3), S18-S24.
52. Korytkowski, M., Niskanen, L., & Asakura, T. (2005). FlexPen: Addressing issues of confidence and convenience in insulin delivery. Clinical Therapeutics, 27(Suppl. B), S89-S100.
53. Krssak, M., Brehm, A., Bernroider, E., Anderwald, C., Nowotny, P., Dalla Man, C., Roden, M. (2004). Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes, 53, 3048-3056.
54. Kunt, T., & Snoek, F. J. (2009). Barriers to insulin initiation and intensification and how to overcome them. International Journal of Clinical Practice, 63(Suppl. 164), 6-10.
55. Lane, W., Weinrib, S., & Rappaport, J. (2011). The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technology and Therapeutics, 13, 592-595.
56. LaSalle, J. R. (2010). Empowering patients during insulin initiation: A real-world approach. Journal of the American Osteopathic Association, 110, 69-78.
57. Levy, J., Atkinson, A. B., Bell, P. M., McCance, D. R., & Hadden, D. R. (1998). Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet Study. Diabetic Medicine, 15, 290-296.
58. Lustman, P. J., & Clouse, R. E. (2005). Depression in diabetic patients: The relationship between mood and glycemic control. Journal of Diabetes and its Complications, 19, 113-122.
59. Marre, M. (2002). Before oral agents fail: The case for starting insulin early. International Journal of Obesity and Related Metabolic Disorders, 26(Suppl. 3), S25-S30.
60. Marre, M., Shaw, J., Brandle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., ...LEAD-1 SU Study Group. (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine, 26, 268-278.
61. Meece, J. (2006). Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educator, 32(Suppl. 1), 9S-18S.
62. Meneghini, L., Koenen, C., Weng, W., & Selam, J. L. (2007). The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study. Diabetes, Obesity & Metabolism, 9, 902-913.
63. Meneghini, L., Liebl, A., & Abrahamson, M. J. (2010). Insulin detemir: A historical perspective on a modern basal insulin analogue. Primary Care Diabetes, 4(Suppl. 1), S31-S42.
64. Mitri, J., & Hamdy, O. (2009). Diabetes medications and body weight. Expert Opinion on Drug Safety, 8, 573-584.
65. Monnier, L., Lapinski, H., & Colette, C. (2003). Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care, 26, 881-885.
66. Mooradian, A. D., Bernbaum, M., & Albert, S. G. (2006). Narrative review: A rational approach to starting insulin therapy. Annals of Internal Medicine, 145, 125-134.
67. Mudaliar, S., & Henry, R. R. (2009). Incretin therapies: Effects beyond glycemic control. American Journal of Medicine, 122 (6 Suppl.), S25-S36.
68. Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., ...American Diabetes Association; European Association for Study of Diabetes. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32, 193-203.
69. Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., ...LEAD-2 Study Group. (2009). Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 32, 84-90.
70. Neumiller, J. J. (2009). Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Journal of the American Pharmaceutical Association, 49(Suppl. 1), S16-S29.
71. Nichols, G. A., Koo, Y. H., & Shah, S. N. (2007). Delay of insulin addition to oral combination therapy despite inadequate glycemic control: Delay of insulin therapy. Journal of General Internal Medicine, 22, 453-458.
72. Overmann, H., & Heinemann, L. (1999). Injection-meal interval: Recommendations of diabetologists and how patients handle it. Diabetes Research and Clinical Practice, 43, 137-142.
73. Peyrot, M., Rubin, R. R., & Khunti, K. (2010). Addressing barriers to initiation of insulin in patients with type 2 diabetes. Primary Care Diabetes, 4(Suppl. 1), S11-S18.
74. Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., ...International DAWN Advisory Panel. (2005). Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care, 28, 2673-2679.
75. Philis-Tsimikas, A., Charpentier, G., Clauson, P., Ravn, G. M., Roberts, V. L., & Thorsteinsson, B. (2006). Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clinical Therapeutics, 28, 1569-1581.
76. Polonsky, W. H., Fisher, L., Earles, J., Dudl, R.J., Lees, J., Mullan, J., & Jackson, R. A. (2005a). Assessing psychosocial distress in diabetes: Development of the diabetes distress scale. Diabetes Care, 28, 626-631.
77. Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005b). Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care, 28, 2543-2545.
78. Pournaras, D. J., Osborne, A., Hawkins, S. C., Vincent, R. P., Mahon, D., Ewings, P., le Roux, C. W. (2010). Remission of type 2 diabetes after gastric bypass and banding: Mechanisms and 2 year outcomes. Annals of Surgery, 252, 966-971.
79. Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., ...for the 1860-LIRA-DPP-4 Study Group. (2010). Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet, 375, 1447-1456.
80. Raccah, D., Hanaire-Broutin, H., Sert-Langeron, C., Brin, S., Chabrier, G., Fontaine, P. M., Eschwège, E. (2006). Insulin initiation in type 2 diabetic patients admitted in hospital in France and follow-up at 1 year. The IDAHO 2 study. Diabetes & Metabolism, 32, 244-250.
81. Raslová, K., Bogoev, M., Raz, I., Leth, G., Gall, M. A., & Hâncu, N. (2004). Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes Research and Clinical Practice, 66, 193-201.
82. Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. L. (2008). Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 2, CD006739.
83. Riddle, M. C. (2004). Timely initiation of basal insulin. American Journal of Medicine, 116(Suppl. 3A), 3S-9S.
84. Riddle, M. C., Rosenstock, J., & Gerich, J.; Insulin Glargine 4002 Study Investigators. (2003). The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 26, 3080-3086.
85. Rodbard, H. W., Blonde, L., Braithwaite, S. S., Brett, E. M., Cobin, R. H., Handelsman, Y., ...AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. (2007). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice, 13(Suppl. 1), 1-68.
86. Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008). A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51, 408-416.
87. Rubino, A., McQuay, L. J., Gough, S. C., Kvasz, M., & Tennis, P. (2007). Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: A population-based analysis in the UK. Diabetic Medicine, 24, 1412-1418.
88. Russell-Jones, D. (2009). Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Molecular and Cellular Endocrinology, 297, 137-140.
89. Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., ...Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. (2009). Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia, 52, 2046-2055.
90. Shyangdan, D. S., Royle, P. L., Clar, C., Sharma, P., & Waugh, N. R. (2010). Glucagon-like peptide analogues for type 2 diabetes mellitus: Systematic review and meta-analysis. Biomed Central Endocrine Disorders, 10:20, doi:.
91. Snoek, F. J. (2002). Breaking the barriers to optimal glycaemic control-what physicians need to know from patients' perspectives. International Journal of Clinical Practice, 56(Suppl. 129), 80-84.
92. Tinahones, F. J., Martin, M., Cardona, F., & Macias-Gonzalez, M. (2008). Visceral fat mass is patients with type 2 diabetes is reduced during insulin detemir-based basal bolus therapy, whereas it is increased during NPH-insulin-based basal bolus therapy. Obesity & Metabolism, 4, 165-168.
93. Tran, K., Banerjee, S., Li, H., Cimon, K., Daneman, D., Simpson, S. H., & Campbell, K. (2007). Long-acting insulin analogues for diabetes mellitus: Meta-analysis of clinical outcomes and assessment of cost effectiveness. Technology report number 92. Ottawa: Canadian Agency for Drugs and Technologies in Health. Retrieved from
94. Tripathy, D., & Chavez, A. O. (2010). Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. Current Diabetes Reports, 10, 184-191.
95. Turner, R. C., Cull, C. A., Frighi, V., & Holman, R. R. (1999). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA, 281, 2005-2012.
96. Tzefos, M., & Olin, J. L. (2010). Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Annals of Pharmacotherapy, 44, 1294-1300.
97. UK Prospective Diabetes Study (UKPDS) Group. (1995). UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes. A progressive disease. Diabetes, 44, 1249-1258.
98. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853.
99. Valensi, P., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., ...IMPROVE Study Group Expert Panel. (2008). The IMPROVE study - a multinational, observational study in type 2 diabetes: Baseline characteristics from eight national cohorts. International Journal of Clinical Practice, 62, 1809-1819.
100. WHO. (2004). Self-management support for chronic conditions using 5As. Retrieved from
101. Yoon, N. M., Cavaghan, M. K., Brunelle, R. L., & Roach, P. (2009). Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clinical Therapeutics, 31, 1511-1523.
102. Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., ...LEAD-4 Study Investigators. (2009). Efficacy and safety efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care, 32, 1224-1230.
103. Zinman, B., Hoogwerf, B. J., Garcia, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D., Brodows, R. G. (2007). The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial. Annals of Internal Medicine, 146, 477-485.